First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study

@inproceedings{Schwarting2016FirstRI,
  title={First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study},
  author={Andreas Schwarting and Johann Schr{\"o}der and Tobias Alexander and Marc Schmalzing and Christoph Fiehn and Christof Specker and Alessandra G Perna and Constanze Cholmakow-Bodechtel and Volker B. Koscielny and Heike Carnarius},
  booktitle={Rheumatology and therapy},
  year={2016}
}
OBSErve Germany was the first observational study of belimumab as add-on treatment for systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively collecting data from 102 SLE patients, 6 months before and after belimumab initiation. Most patients had moderate or severe SLE and several SLE manifestations. After 6 months of belimumab treatment, 78% of patients showed an improvement in overall disease activity of at least 20% in their physician's judgment and for 42… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Treatment of severe lupus nephritis: the new horizon

  • TM Chan
  • Nat Rev Nephrol
  • 2015
1 Excerpt

erythematosus : a registry - based cohort study in Denmark

  • M Petri, B Bechtel, G Dennis
  • 2015

Early clinical experiences with belimumab in Polish patients with systemic lupus erythematosus

  • M Majdan, EJ Kucharz, S Jeka, S Sierakowski, P Leszczynski, W Tlustochowicz
  • Ann Rheum Dis
  • 2014

Evolution of patients with systemic lupus erythematous treated with belimumab in clinical practice settings

  • J Cortes, JL Andreu, J Calvo-Alen
  • Arthritis Rheumatol
  • 2014

Similar Papers

Loading similar papers…